Completed PHASE2 INTERVENTIONAL 3-arm NCT00413166

All-trans Retinoic Acid, and Arsenic +/- Idarubicin

Treatment of Acute Promyelocytic Leukemia (APL) With All-Trans Retinoic Acid, and Arsenic +/- Idarubicin

Sponsor: M.D. Anderson Cancer Center

Interventions All-Trans Retinoic Acid (ATRA) Arsenic Trioxide (ATO) Gemtuzumab Ozogamicin Idarubicin

Updated 10 times since 2017 Last updated: Apr 23, 2019 Started: Dec 31, 2006 Primary completion: Feb 29, 2016 Completion: Feb 29, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Acute Promyelocytic Leukemia and is currently completed. M.D. Anderson Cancer Center leads this study, which shows 10 recorded versions since 2006 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Jun 2019 — Jan 2021 [monthly]

Completed PHASE2
May 2019 — Jun 2019 [monthly]

Completed PHASE2
Jun 2018 — May 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States